WO2008021956A3 - Acylaminoheteroaryl hepatitis c virus protease inhibitors - Google Patents

Acylaminoheteroaryl hepatitis c virus protease inhibitors Download PDF

Info

Publication number
WO2008021956A3
WO2008021956A3 PCT/US2007/075580 US2007075580W WO2008021956A3 WO 2008021956 A3 WO2008021956 A3 WO 2008021956A3 US 2007075580 W US2007075580 W US 2007075580W WO 2008021956 A3 WO2008021956 A3 WO 2008021956A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
present invention
subject
virus
compounds
Prior art date
Application number
PCT/US2007/075580
Other languages
French (fr)
Other versions
WO2008021956A2 (en
Inventor
Deqiang Niu
Joel Moore
Dong Liu
Yonghua Gai
Zhigang Chen
Yat Sun Or
Zhe Wang
Original Assignee
Enanta Pharm Inc
Deqiang Niu
Joel Moore
Dong Liu
Yonghua Gai
Zhigang Chen
Yat Sun Or
Zhe Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/503,502 priority Critical
Priority to US11/503,502 priority patent/US7605126B2/en
Application filed by Enanta Pharm Inc, Deqiang Niu, Joel Moore, Dong Liu, Yonghua Gai, Zhigang Chen, Yat Sun Or, Zhe Wang filed Critical Enanta Pharm Inc
Publication of WO2008021956A2 publication Critical patent/WO2008021956A2/en
Publication of WO2008021956A3 publication Critical patent/WO2008021956A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention discloses compounds of formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
PCT/US2007/075580 2006-08-11 2007-08-09 Acylaminoheteroaryl hepatitis c virus protease inhibitors WO2008021956A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/503,502 2006-08-11
US11/503,502 US7605126B2 (en) 2006-08-11 2006-08-11 Acylaminoheteroaryl hepatitis C virus protease inhibitors

Publications (2)

Publication Number Publication Date
WO2008021956A2 WO2008021956A2 (en) 2008-02-21
WO2008021956A3 true WO2008021956A3 (en) 2008-11-13

Family

ID=39051607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075580 WO2008021956A2 (en) 2006-08-11 2007-08-09 Acylaminoheteroaryl hepatitis c virus protease inhibitors

Country Status (2)

Country Link
US (1) US7605126B2 (en)
WO (1) WO2008021956A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
DK1999129T3 (en) * 2005-10-11 2011-02-07 Intermune Inc Compounds and methods for inhibiting the replication of hepatitis C virus
RU2008152171A (en) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) New inhibitors of viral replication of hepatitis C
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) * 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) * 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
KR20090101372A (en) * 2007-01-08 2009-09-25 페노믹스 코포레이션 Macrocyclic hepatitis c protease inhibitors
AP200905053A0 (en) * 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
TW200902520A (en) 2007-05-10 2009-01-16 Intermune Inc Novel peptide inhibitors of hepatitis C virus replication
US20090111757A1 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
JP5529036B2 (en) * 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド Fluorinated tripeptide HCV serine protease inhibitor
US8283309B2 (en) * 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
RU2523790C2 (en) 2007-12-21 2014-07-27 Авила Терапьютикс, Инк. Inhibitors of protease of hepatitis c virus and their application
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
KR101683559B1 (en) * 2007-12-21 2016-12-08 셀진 아빌로믹스 리서치, 인코포레이티드 HCV protease inhibitors and uses thereof
RU2490272C2 (en) * 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Macrocyclic serine protease inhibitors
JP5490778B2 (en) * 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Fluorinated macrocycles as hepatitis C virus inhibitors
BRPI0911260A2 (en) * 2008-04-15 2015-09-29 Intermune Inc compound, pharmaceutical composition, method of inhibiting ns3 / ns4 protease activity in vitro, and uses of compounds
US8163921B2 (en) * 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211891B2 (en) * 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (en) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 Hcv protease inhibitors
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) * 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) * 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) * 2008-09-11 2010-04-30 Enanta Pharm Inc macrocyclic serine protease inhibitors of hepatitis c
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR075584A1 (en) * 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS COMPRISING beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine ACID AND DERIVATIVE isoindole carboxylic acid and its uses. COMPOUND.
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
EP2477980B1 (en) * 2009-09-15 2016-06-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
EA201290128A1 (en) * 2009-09-28 2013-01-30 Интермьюн, Инк. New macrocyclic inhibitors of hepatitis c virus replication
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MX2013007698A (en) 2010-12-30 2013-08-15 Abbvie Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors.
MX2013007677A (en) 2010-12-30 2013-07-30 Abbvie Inc Macrocyclic hepatitis c serine protease inhibitors.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102911254A (en) * 2011-08-02 2013-02-06 上海唐润医药科技有限公司 HCV (hepatitis C virus) protease inhibitor
WO2014058794A1 (en) 2012-10-08 2014-04-17 Abbvie Inc. Compounds useful for making hcv protease inhibitors
ES2613766T3 (en) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Carbamate derivatives of hexadecahydrocyclopropa (e) pyrrolo (1,2-a) (1,4) diazacyclopentadecinyl substituted with 9-methyl as inhibitors of non-structural protease 3 (NS3) for the treatment of hepatitis C virus infections
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US7041698B2 (en) * 2002-05-20 2006-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5347775A (en) * 1993-07-27 1994-09-20 Jorge Santos Hurricane shutters for windows
US5430982A (en) * 1994-03-24 1995-07-11 Bane; Robert F. Storm panel system with continuous run rails and spring clips
US5603190A (en) * 1995-01-26 1997-02-18 Sanford; Elizabeth A. Storm panel and attachment apparatus
US5620037A (en) * 1995-05-08 1997-04-15 Apostolo; Mauricio C. Mortised removable storm shutter
US5855099A (en) * 1997-03-14 1999-01-05 Hoffman; Robert E. Sectional storm panel assembly
US6269597B1 (en) * 1999-03-11 2001-08-07 John W. Haas Storm panel support apparatus for windows
US6189264B1 (en) * 1999-07-30 2001-02-20 Diveroli Oscar Hurricane storm panel and method of installation
US20030159373A1 (en) * 2002-02-27 2003-08-28 Shihwei Lien Hurricane/storm device for windows and doors
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US20050193651A1 (en) * 2004-03-08 2005-09-08 Cameron Kirk Shutter assembly for storm and security protection
BRPI0517463A (en) 2004-10-21 2008-10-07 Pfizer Virus protease inhibitors of hepatitis C, compositions and treatments using the same
EP1924594A2 (en) * 2005-07-25 2008-05-28 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9526769B2 (en) * 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US8268776B2 (en) * 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US20070281884A1 (en) * 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US7041698B2 (en) * 2002-05-20 2006-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9527885B2 (en) 2011-05-05 2016-12-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
US7605126B2 (en) 2009-10-20
US20080039470A1 (en) 2008-02-14
WO2008021956A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
TWI412368B (en) Compounds and pharmaceutical compositions for the treatment of viral infections
CA2568186C (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RU2490272C2 (en) Macrocyclic serine protease inhibitors
TWI375679B (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
UA97351C2 (en) Coumarin derivative having antitumor activity
UA83046C2 (en) Hepatitis c inhibitor compounds, pharmaceutical composition based thereon
PH12012501881A1 (en) 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication
MX2010008699A (en) Heterocyclic derivatives as hepatitis c virus inhibitors.
TW200716095A (en) Method of treating interferon non-responders using HCV protease inhibitor
IL212485A (en) Aminotetrahydropyran compounds, pharmaceutical compositions comprising same and use thereof in therapy
MX2010008531A (en) Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors.
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
NZ564550A (en) Macrocyclic inhibitors of hepatitis C virus
WO2008070447A3 (en) Anti-viral compounds
NO20062101L (en) Serine protease inhibitors, particularly HCV NS3-NS4A protease
MX2012005810A (en) Amino oxazine derivatives.
WO2006122011A3 (en) Thiazole compounds and methods of use
WO2007008657A3 (en) Hepatitis c virus inhibitors
TW200536528A (en) Novel inhibitors of hepatitis C virus NS3 protease
WO2005087731A8 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
MA34013B1 (en) Inhibitors of Hepatitis C virus
UY35259A (en) macrocyclic serine protease inhibitors of hepatitis c
EP1719773A4 (en) Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
TW200529822A (en) Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813943

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07813943

Country of ref document: EP

Kind code of ref document: A2